Search for a trial

A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

This study has been transitioned to CTIS with ID 2023-508214-42-00 check the CTIS register for the current data. Primary: To compare the efficacy of AMG 510 versus docetaxel as assessed by progression-free survival (PFS) in previously treated…